Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: The role of bosentan

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 9, 2008, Pages 1077-1084

  Antoniu, Sabina Antonela ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Bosentan; Endothelin 1; Idiopathic pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ENDOTHELIN 1; ETANERCEPT; GAMMA1B INTERFERON; GLUTATHIONE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; PHOSPHODIESTERASE V INHIBITOR; PIRFENIDONE; PLACEBO; PREDNISONE; PROSTACYCLIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 BLOCKING AGENT;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERCISE TOLERANCE; FIBROGENESIS; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG GAS EXCHANGE; LUNG HEMODYNAMICS; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

EID: 51549109927     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.9.1077     Document Type: Review

References (52)

1. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174(7):803-9
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64
3. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26(4):693-702
4. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176(7):636-43
5. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351(9095):24-7
6. Williams T, Wilson JW. Challenges in pulmonary fibrosis: 7-novel therapies and lung transplantation. Thorax 2008;63(3):277-84
7. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134(2):136-51
8. Willis BC, Dubois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006;3(4):377-82
9. Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Ann Rev Med 2004;55:395-417
10. Ask K, Martin GE, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 2006;3(4):389-93
11. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol 2006; (176 Pt 1). In: Mocada S, Higgs A, editors, The vascular endothelium. Heidelberg: Springer; 2006. p. 295-329
12. Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006;7(11):1487-501
13. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156(2 Pt 1):600-8
14. Mutsaers SE, Foster ML, Chambers RC, et al. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 1998;18(5):611-9
15. Wendel M, Petzold A, Koslowski R, et al. Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem Cell Biol 2004;122(5):507-17
16. Hocher B, Schwarz A, Fagan KA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000;23(1):19-26
17. Chalmers GW, MacLeod KJ, Sriram S, et al. Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. Eur Respir J 1999;13(6):1288-92
18. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001;56(1):30-5
19. Trakada G, Tsourapis S, Marangos M, Spiropoulos K. Arterial and bronchoalveolar lavage fluid endothelin-1 concentration in asthma. Respir Med 2000;94(10):992-6
20. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341(8860):1550-4
21. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16(2):187-93
22. Uguccioni M, Pulsatelli L, Grigolo B, et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995;48(4):330-4
23. Simler NR, Brenchley PE, Horrocks AW, et al. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004;59(7):581-5
24. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151(3):831-41
25. Watts K, Gazdhar A, Spiteri M, Geiser TK. BALF from patients with IPF reduce alveolar epithelial wound repair in vitro by an endothelin-1 dependent mechanism. Am Thorac Soc Int Conf 2007;175:A735
26. Shi-Wen Y, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/ Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15(6):2707-19
27. Carpagnano GE, Kharitonov SA, Wells AU, et al. Increased vitronectin and endothelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration 2003;70(2):154-60
28. Kim KK, Chapman HA. Endothelin-1 as initiator of epithelial-mesenchymal transition: potential new role for endothelin-1 during pulmonary fibrosis. Am J Respir Cell Mol Biol 2007;37(1):1-2
29. Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-β1. Am J Respir Cell Mol Biol 2007;37(1):38-47
30. Shi-Wen X, Kennedy L, Renzoni EA, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum 2007;56(12):4189-94
31. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79(6):2122-31
32. Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3(6):887-900
33. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31(2):407-15
34. Bosentan (Tracleer®) in Clinical Development. Available from: http://www.actelion.com/uninet/www/wwwi_main_p.nsf/Content/ Bosentan+Tracleer+in+Clinical+Development [Last accessed 16 July 2008]
35. Armstrong L, Millar AB. The effect of bosentan on VEGF isoform and receptor expression by human pulmonary microvascular endothelial cells (HMVEC-I, Cambrex), and human lung fibroblasts (FB). Am Thorac Soc Int Conf 2006;173:A188
36. Schroll S, Sebah D, Arzt M, et al. Improvement of bleomycin induced pulmonary hypertension and pulmonary fibrosis by the endothelin antagonist bosentan. Am Thorac Soc Int Conf 2006;173:A420
37. Mutsaers SE, Marshall RP, Goldsack NR, et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998;11(2-3):221-5
38. Gunther A, Enke B, Markart P, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 2007;29(4):713-9
39. King Tejr BJ, Brown KK, Du Bois RM, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81
40. Seibold J, Black CM, Denton CP et al. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis: the BUILD 2 study [abstract A243]. ATS Poster; 19-24 May 2006; San Diego, CA, USA
41. Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110(4):278-82
42. Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998;53(6):469-76
43. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144(2):291-6
44. Zisman DA, Lynch JP 3rd, Toews GB, et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000;117(6):1619-26
45. Segel MJ, Izbicki G, Cohen PY, et al. Role of interferon-γ in the evolution of murine bleomycin lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;285(6):L1255-62
46. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350(2):125-33
47. Bajwa EK, Ayas NT, Schulzer M, et al. Interferon-γ1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005;128(1):203-6
48. Shahzeidi S, Sarnstrand B, Jeffery PK, et al. Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur Respir J 1991;4(7):845-52
49. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353(21):2229-42
50. Horowitz JC, Thannickal VJ. Idiopathic pulmonary fibrosis: new concepts in pathogenesis and implications for drug therapy. Treat Respir Med 2006;5(5):325-42
51. Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother 2004;5(8):1671-86
52. Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs 2006;15(7):823-8